Johnson & Johnson forecasts $100.30 billion to $101.30 billion revenue for 2026, beating Q1 estimates and raising full-year guidance.
Johnson & Johnson set a $278.53 price target after reporting Q1 2026 revenue of $24.06 billion, topping consensus by 1.89%. Adjusted EPS of $2.70 extended a four-quarter beat streak, prompting raised full-year guidance of $100.30 billion to $101.30 billion in revenue and $11.45 to $11.65 in adjusted EPS.
The company’s 28 billion-dollar brands, including DARZALEX at $3.96 billion (+22.5%), drove growth, outpacing peers facing patent cliffs. JNJ’s 64-year dividend streak and pipeline strength, highlighted by ICOTYDE as a potential blockbuster, underpin the bullish outlook. Shares trade near a 52-week high of $269.43, up 25.56% year-to-date.
Analysts see 8.39% upside from the recent close of $256.98, citing derisked pipeline and operational momentum post-DePuy Synthes separation.